Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cells
Flim-Flam Stem Cell Artists Targeted by CIRM
Posted: August 25, 2013 at 2:57 am
The California stem cell agency has
joined with other prestigious stem cell organizations to help put a
stop to the flim-flam artists that prey on desperate people by
promising miracle cures from stem cell treatments.
joined with other prestigious stem cell organizations to help put a
stop to the flim-flam artists that prey on desperate people by
promising miracle cures from stem cell treatments.
The agency announced the action today on its blog, declaring that it has posted a new patient advisory document that provides a “ robust and detailed set of issues
patients should consider when making treatment decisions.”
patients should consider when making treatment decisions.”
Don Gibbons, CIRM's senior science and
education communications officer and author of the blog item, said
the document addresses one of his special concerns: Internet “ads
that come up on web searches and seem to be offering everything to
everyone.”
education communications officer and author of the blog item, said
the document addresses one of his special concerns: Internet “ads
that come up on web searches and seem to be offering everything to
everyone.”
Some of those ads can be found on many stem cell-related web sites, including this one, that carry ads that are placed there
automatically by Google.
automatically by Google.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Flim-Flam Stem Cell Artists Targeted by CIRM
California Stem Cell Agency Spending: Where the Money Is Going
Posted: August 25, 2013 at 2:57 am
Analysis of CIRM funding by Pat Olson, executive director of CIRM scientific activities July 2013 |
The California stem cell agency will
have committed $472 million to translational research – a key to
commercializing stem cell therapies – if it awards the full $70
million in new grants and loans slated to come before its governing
board next week.
have committed $472 million to translational research – a key to
commercializing stem cell therapies – if it awards the full $70
million in new grants and loans slated to come before its governing
board next week.
The nearly $500 million will amount to
about 17 percent of its funding so far, according to an analysis last
month by Pat Olson, the agency's executive director of scientific activities. The
largest percentage of the agency's cash, however, will be going for
“development” – 35 percent or $970 million. Olson defined
“development” as “essentially our IND enabling, our
preclinical development programs and our clinical development
programs.”
about 17 percent of its funding so far, according to an analysis last
month by Pat Olson, the agency's executive director of scientific activities. The
largest percentage of the agency's cash, however, will be going for
“development” – 35 percent or $970 million. Olson defined
“development” as “essentially our IND enabling, our
preclinical development programs and our clinical development
programs.”
Basic research is to receive 17 percent
or about $469 million with buildings and facilities taking up $443
million or 16 percent. Training and career development has consumed
about 15 percent or $414 million.
or about $469 million with buildings and facilities taking up $443
million or 16 percent. Training and career development has consumed
about 15 percent or $414 million.
However, those calculations include
$577 million in funds that have been allocated but not yet awarded.
Another $491 million is “concept approved” but also not awarded.
The agency's governing board could change those allocations or
withdraw approval of concepts, although it has not yet shown signs
that it might do so.
$577 million in funds that have been allocated but not yet awarded.
Another $491 million is “concept approved” but also not awarded.
The agency's governing board could change those allocations or
withdraw approval of concepts, although it has not yet shown signs
that it might do so.
The agency will run out of money for
new grants in 2017 and is examining the possibility of generating
more cash through some sort of public-private partnership. To develop
support for continued funding, the agency is under pressure to
generate results that will resonate with the public and potential
private funding sources. Those results are most likely to come from
a late stage translational/clinical trial effort.
new grants in 2017 and is examining the possibility of generating
more cash through some sort of public-private partnership. To develop
support for continued funding, the agency is under pressure to
generate results that will resonate with the public and potential
private funding sources. Those results are most likely to come from
a late stage translational/clinical trial effort.
Here is a link to CIRM's translational portfolio as of September 2012.
(An earlier version of this item incorrectly said that the agency would run out of money for new grants in 2013. The correct year is 2017,.)
Posted in Stem Cells, Stem Cell Therapy
Comments Off on California Stem Cell Agency Spending: Where the Money Is Going
California Stem Cell Agency's $150,000 Search for Its Financial Future
Posted: August 25, 2013 at 2:57 am
A San Francisco consultant, who is
often known as an “economic therapist,” has been selected to
devise a “strategic road map” for the financial future of the $3
billion California stem cell agency.
often known as an “economic therapist,” has been selected to
devise a “strategic road map” for the financial future of the $3
billion California stem cell agency.
James Gollub: 'economic therapist' Gollub Associates photo |
James Gollub, managing director of the
firm bearing his name, is under a $150,000 contract to lay out by
this fall a detailed plan for the agency. The nine-year-old research
effort is scheduled to run out of money for new awards in 2017.
firm bearing his name, is under a $150,000 contract to lay out by
this fall a detailed plan for the agency. The nine-year-old research
effort is scheduled to run out of money for new awards in 2017.
Gollub was selected after the agency
posted a request for proposals (RFP) last spring. The RFP assumed an
additional $50 million to $200 million in a onetime “public
investment.” The RFP also assumed additional private funding of a
yet-to-be-determined nature.
posted a request for proposals (RFP) last spring. The RFP assumed an
additional $50 million to $200 million in a onetime “public
investment.” The RFP also assumed additional private funding of a
yet-to-be-determined nature.
Gollub is described as a co-founder of the field of cluster-based economic development. One web site said he
is known as an “economic therapist.” The website for his current firm says,
is known as an “economic therapist.” The website for his current firm says,
“A leading expert in innovation
bridge building....
“Global experience assisting
universities, institutes, government agencies and public-private
partnerships link innovation sources to innovation
seekers.
“Committed to the goal of increasing flow of needed
solutions, optimizing financial returns and sustainable economic
impacts from innovation.”
Gollub's current firm dates back to
March of this year. His Linked In profile says,
March of this year. His Linked In profile says,
“James Gollub Associates
(JGA) LLC was launched to build on 36 years of Gollub’s
professional research and consulting experience. That experience
began with 16 years at SRI International, three years at
DRI/McGraw-Hill, five years at IDeA, nine years at ICF International
and three years with E-Cubed Ventures LLC. During that
time Gollub has worked globally to deliver
economic strategies for over 30 national, state and metropolitan
regions, develop strategies to accelerate growth of new industries
(clusters), plan public and private R&D institutes and advise on
over 15 science and technology parks.”
The need for a financial transition plan for CIRM was publicly identified as long ago as 2009 by the Little Hoover Commission in its lengthy study and has been reiterated periodically by other bodies since then. Under the terms of Prop. 71, which created the agency, CIRM has only a 10-year authority to issue state bonds, the borrowed funds that have sustained the research effort. Legal maneuvering blocked the issuance of bonds until 2007.
The California Stem Cell Report asked
the stem cell agency on May 31 for a copy of Gollub's response to the
RFP. Yesterday we asked for a copy of the contract with Gollub. Those
documents will be published when they are received.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/tncFJBJJM5I/california-stem-cell-agencys-150000.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on California Stem Cell Agency's $150,000 Search for Its Financial Future
A $2 Million Bill: Outside Contracting by California Stem Cell Agency
Posted: August 25, 2013 at 2:57 am
The $3 billion California stem cell
agency this week posted a list of its outside contractors, who range
from a a $25,000 stem cell licensing consultant to a $550,000-a-year law firm.
agency this week posted a list of its outside contractors, who range
from a a $25,000 stem cell licensing consultant to a $550,000-a-year law firm.
The agency expects to spend $2
million during 2013-14 on outside contracting, down from $2.9 million
in 2012-13. This week's report covers the 2012-13 year.
million during 2013-14 on outside contracting, down from $2.9 million
in 2012-13. This week's report covers the 2012-13 year.
Outside contracting is the second
largest item in the agency's budget, which is slated to spend $17.4
million this fiscal year for operational expenses, up 5 percent
from last year's spending. The largest amount, $12.2 million, goes
for salaries and benefits. (For more on the budget, see here, here
and here.)
largest item in the agency's budget, which is slated to spend $17.4
million this fiscal year for operational expenses, up 5 percent
from last year's spending. The largest amount, $12.2 million, goes
for salaries and benefits. (For more on the budget, see here, here
and here.)
Topping the contractor list is the law
firm of Remcho, Johansen & Purcell of San Leandro, Ca., which had
the $550,000 contract. CIRM, as the agency is known, reported that Remcho came in under
budget by $95,595. That contrasts to some previous years when the
firm, which has represented the stem cell agency since its inception,
required additional cash on top of its original contract. James
Harrison of the Remcho firm is its face at the agency and is
designated as the outside counsel to the agency's governing board. In
all, the agency is slated to spend $2.2 million on legal expenses,
including in-house work.
firm of Remcho, Johansen & Purcell of San Leandro, Ca., which had
the $550,000 contract. CIRM, as the agency is known, reported that Remcho came in under
budget by $95,595. That contrasts to some previous years when the
firm, which has represented the stem cell agency since its inception,
required additional cash on top of its original contract. James
Harrison of the Remcho firm is its face at the agency and is
designated as the outside counsel to the agency's governing board. In
all, the agency is slated to spend $2.2 million on legal expenses,
including in-house work.
David Earp is the stem cell licensing
contractor. He was paid only $13,125 on his $25,000 contract during
2012-13. It is unclear whether he will be paid the $11,875 balance.
Earp was chief patent counsel and senior vice president for business
development for Geron before it dropped its stem cell program. Earp was heavily involved in the $25 million loan that CIRM made to Geron in 2011. In
February 2008, he testified before CIRM about its then proposed loan
program.
contractor. He was paid only $13,125 on his $25,000 contract during
2012-13. It is unclear whether he will be paid the $11,875 balance.
Earp was chief patent counsel and senior vice president for business
development for Geron before it dropped its stem cell program. Earp was heavily involved in the $25 million loan that CIRM made to Geron in 2011. In
February 2008, he testified before CIRM about its then proposed loan
program.
The list of contractors included
$200,000 to the AlphaMed Press of Durham, N.C., as seed funding for a
stem cells translational journal, $156,434 to Hyatt Hotels for the
meeting of CIRM grant recipients, $250,000 to Kutir Corp. of Newark, Ca., for
informational technology services and $290,000 to the Mitchell
Group of Woodland Hills, Ca., also for information technology services.
$200,000 to the AlphaMed Press of Durham, N.C., as seed funding for a
stem cells translational journal, $156,434 to Hyatt Hotels for the
meeting of CIRM grant recipients, $250,000 to Kutir Corp. of Newark, Ca., for
informational technology services and $290,000 to the Mitchell
Group of Woodland Hills, Ca., also for information technology services.
The list of contractors will be
presented to the CIRM governing board at its meeting next week. The
list does not usually trigger any significant discussion.
presented to the CIRM governing board at its meeting next week. The
list does not usually trigger any significant discussion.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on A $2 Million Bill: Outside Contracting by California Stem Cell Agency
New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency
Posted: August 25, 2013 at 2:57 am
The $3 billion California stem cell
agency wants to recruit major biotech and venture capital firms to
help provide tens of millions of dollars in research awards to
California enterprises.
agency wants to recruit major biotech and venture capital firms to
help provide tens of millions of dollars in research awards to
California enterprises.
It's part of a move to “jump start”
partnerships in a relatively new, $80 million, business-friendly program that is aimed at pushing therapies into the
marketplace. The recruitment plan will come before the agency's governing board at its meeting next Wednesday in San Diego.
partnerships in a relatively new, $80 million, business-friendly program that is aimed at pushing therapies into the
marketplace. The recruitment plan will come before the agency's governing board at its meeting next Wednesday in San Diego.
Participating companies will have a
special relationship with the state agency, including early input
into concept funding proposals prior to their being presented to the
agency's governing board. The “industry collaborators” will also
be able to attend agency workshops and meetings involving
hundreds of grant recipients. Presumably other, non-collaborating
firms would be barred.
special relationship with the state agency, including early input
into concept funding proposals prior to their being presented to the
agency's governing board. The “industry collaborators” will also
be able to attend agency workshops and meetings involving
hundreds of grant recipients. Presumably other, non-collaborating
firms would be barred.
Other provisions of the plan call for
special event-hosting arrangements aimed at creating more
collaborations and posting of information from the selected
collaborators on the CIRM website.
special event-hosting arrangements aimed at creating more
collaborations and posting of information from the selected
collaborators on the CIRM website.
According to a CIRM staff document, the
initiative would be limited to biotech and pharmaceutical firms with
a market capitalization of at least $500 million and “qualified
venture capital firms.” The document did not define what a
“qualified a venture capital firm” is. The document also appeared
to bar participation of privately held firms because of the “market
capitalization” criteria, which typically uses a formula involving
publicly traded shares.
initiative would be limited to biotech and pharmaceutical firms with
a market capitalization of at least $500 million and “qualified
venture capital firms.” The document did not define what a
“qualified a venture capital firm” is. The document also appeared
to bar participation of privately held firms because of the “market
capitalization” criteria, which typically uses a formula involving
publicly traded shares.
Elona Baum, the agency's general
counsel and vice president, business development, said in a statement
provided to the California Stem Cell Report,
counsel and vice president, business development, said in a statement
provided to the California Stem Cell Report,
“This is aimed at trying to jump
start the creation of the partnerships that are required to satisfy
the commercial validation requirements of the Strategic Partnership
Funding Initiative so that timelines are better synced-up as between
our review and approval cycles for the Strategic Partnership RFAs and
the lengthy time required for investors to conduct due diligence and
negotiate an agreement with prospective applicants to Strategic
Partnership RFAs. CIRM's independent review and approval
remains the same and is wholly independent. While there may be input
given to a particular RFA it only at the high level concept stage and
of course CIRM has no obligation to agree. In the context of the
Strategic Partnership awards, CIRM wants to fund innovative high
quality science that has attracted additional investors.
Investors will help leverage CIRM fund and will be an important
source of future funding to further the project.”
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/ZtmnBmRh5K0/new-ties-to-big-pharma-and-venture.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency
California Stem Cell Agency’s $150,000 Search for Its Financial Future
Posted: August 25, 2013 at 2:57 am
A San Francisco consultant, who is
often known as an “economic therapist,” has been selected to
devise a “strategic road map” for the financial future of the $3
billion California stem cell agency.
often known as an “economic therapist,” has been selected to
devise a “strategic road map” for the financial future of the $3
billion California stem cell agency.
James Gollub: 'economic therapist' Gollub Associates photo |
James Gollub, managing director of the
firm bearing his name, is under a $150,000 contract to lay out by
this fall a detailed plan for the agency. The nine-year-old research
effort is scheduled to run out of money for new awards in 2017.
firm bearing his name, is under a $150,000 contract to lay out by
this fall a detailed plan for the agency. The nine-year-old research
effort is scheduled to run out of money for new awards in 2017.
Gollub was selected after the agency
posted a request for proposals (RFP) last spring. The RFP assumed an
additional $50 million to $200 million in a onetime “public
investment.” The RFP also assumed additional private funding of a
yet-to-be-determined nature.
posted a request for proposals (RFP) last spring. The RFP assumed an
additional $50 million to $200 million in a onetime “public
investment.” The RFP also assumed additional private funding of a
yet-to-be-determined nature.
Gollub is described as a co-founder of the field of cluster-based economic development. One web site said he
is known as an “economic therapist.” The website for his current firm says,
is known as an “economic therapist.” The website for his current firm says,
“A leading expert in innovation
bridge building....
“Global experience assisting
universities, institutes, government agencies and public-private
partnerships link innovation sources to innovation
seekers.
“Committed to the goal of increasing flow of needed
solutions, optimizing financial returns and sustainable economic
impacts from innovation.”
Gollub's current firm dates back to
March of this year. His Linked In profile says,
March of this year. His Linked In profile says,
“James Gollub Associates
(JGA) LLC was launched to build on 36 years of Gollub’s
professional research and consulting experience. That experience
began with 16 years at SRI International, three years at
DRI/McGraw-Hill, five years at IDeA, nine years at ICF International
and three years with E-Cubed Ventures LLC. During that
time Gollub has worked globally to deliver
economic strategies for over 30 national, state and metropolitan
regions, develop strategies to accelerate growth of new industries
(clusters), plan public and private R&D institutes and advise on
over 15 science and technology parks.”
The need for a financial transition plan for CIRM was publicly identified as long ago as 2009 by the Little Hoover Commission in its lengthy study and has been reiterated periodically by other bodies since then. Under the terms of Prop. 71, which created the agency, CIRM has only a 10-year authority to issue state bonds, the borrowed funds that have sustained the research effort. Legal maneuvering blocked the issuance of bonds until 2007.
The California Stem Cell Report asked
the stem cell agency on May 31 for a copy of Gollub's response to the
RFP. Yesterday we asked for a copy of the contract with Gollub. Those
documents will be published when they are received.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/tncFJBJJM5I/california-stem-cell-agencys-150000.html
Posted in Stem Cells, Stem Cell Therapy
Comments Off on California Stem Cell Agency’s $150,000 Search for Its Financial Future
Stem Cells and Stroke
Posted: August 23, 2013 at 7:46 pm
MIAMI, Fla.
Each year 700 thousand people suffer a stroke in the United States. Until now, the only recovery for paralysis brought on by the stroke was lengthy rehabilitation. Now, a new stem cell therapy is helping stroke patients move again.
James Anderson is a tri-athlete and physical education teacher. He was visiting Florida from Maine when suddenly, I started to feel a little dizzy a little tingling in my right hand and ah I ended up having a stroke, James Anderson told Ivanhoe.
James did not respond to clot busting medication or blockage treatments. So he became paralyzed on the left side of his body. Neurologist Doctor Dileep R. Yavatal treated him as part of a clinical trial, where some of the patients were treated with their own stem cells. While Anderson doesnt know if he was injected with his own stem cells, two months after treatment, Anderson said, "I have had more movement and strength in my legs."
For the clinical trial, stem cells must be injected into the brain no later than two weeks after the stroke occurs. James is now able to move around with a walker, during rehab, and hopes to be able to compete in a triathalon again.
See the rest here:
Stem Cells and Stroke
Posted in Stem Cells
Comments Off on Stem Cells and Stroke
Recent Findings from M. Nishikawa and Co-Researchers Yields New Information on Stem Cells
Posted: August 23, 2013 at 7:46 pm
By a News Reporter-Staff News Editor at Veterinary Week -- Research findings on Stem Cell Research are discussed in a new report. According to news originating from North Hills, California, by VerticalNews correspondents, research stated, "Successful derivations of specific neuronal and glial cells from embryonic stem cells have enormous potential for cell therapies and regenerative medicine. However, the low efficiency, the complexity of induction method, and the need for purification represent obstacles that make their application impractical."
Our news journalists obtained a quote from the research, "In this study, we found that PDGFR alpha(+) cells derived from mouse embryonic stem cells (mESC) can serve as a useful source from which to induce cells that express gamma-aminobutyric-acid (GABA)-releasing (GABAergic) neuronal markers. PDGFR alpha(+) cells were induced from mESC on collagen IV-coated plates in mesenchymal stem cell (MSC) culture medium with limited exposure to retinoic acid, sorted by fluorescence-activated cell sorter and maintained in MSC culture medium containing Y-27632, a Rho-associated kinase inhibitor. We found that supplementation of vascular endothelial growth factor, fibroblast growth factor-basic, and sodium azide (NaN3) to MSC culture medium effectively differentiated PDGFR alpha(+) cells into cells that express GABAergic neuronal markers, such as Pax2, Dlx2, GAD67 NCAM, and tubulin-beta III, while markers for oligodendrocyte (Sox2) and astrocyte (Glast) were suppressed. Immunostaining for GABA showed the majority (86 +/- 5%) of the induced cells were GABA-positive. We also found that the PDGFR alpha(+) cells retained such differentiation potential even after more than ten passages and cryopreservation. In summary, this study presents a simple and highly efficient method of inducing cells that express GABAergic neuronal markers from mESC."
According to the news editors, the research concluded: "Together with its ease of maintenance in vitro, PDGFR alpha(+) cells derived from mESC may serve as a useful source for such purpose."
For more information on this research see: Effective induction of cells expressing GABAergic neuronal markers from mouse embryonic stem cell. In Vitro Cellular & Developmental Biology-Animal, 2013;49(7):479-485. In Vitro Cellular & Developmental Biology-Animal can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA.
The news correspondents report that additional information may be obtained from M. Nishikawa, VAGLAHS Sepulveda, Renal Regenerat Lab, North Hills, CA 91343, United States. Additional authors for this research include N. Yanagawa, S. Yuri, P. Hauser, O.D. Jo and N. Yanagawa.
Keywords for this news article include: Biomedical Engineering, Biomedicine, Neurons, California, North Hills, United States, Bioengineering, Stem Cell Research, Embryonic Stem Cells, Regenerative Medicine, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Originally posted here:
Recent Findings from M. Nishikawa and Co-Researchers Yields New Information on Stem Cells
Posted in Stem Cells
Comments Off on Recent Findings from M. Nishikawa and Co-Researchers Yields New Information on Stem Cells
Yes, you can make a burger out of human stem cells – but you probably wouldn’t want to
Posted: August 22, 2013 at 4:44 pm
After the success of the test-tube burger, Michael Brooks answers the question on everyone in the NS offices lips: "Why not make burgers from human stem cells?"
You are what you eat - or at least you might be. Photograph: Getty Images.
Sometimes the NSs offices resound with provocative questions. Last week, it was: Why not make burgers from human stem cells?
This is not as ridiculous as it might first seem. It would be the pinnacle of ethical carnivorous living, the only way you could eat prime meat with the full, informed consent of the donor.
It wouldnt be cheap. The price of a burger cultured from human cells would make the 250,000 feed, created by the Maastricht University researcher Mark Post and formally presented on 5 August, look like a bargain. Human stem-cell culture for medical research is done under the most onerous safety restrictions and following strict protocols. Culturing human cells for human consumption would be just as onerous (and thus expensive) as it is for medical research because we would have to make sure there was no chance the cells could become infected by viruses or bacteria.
Eating other animals is safer simply because the pathogens that make them ill do not necessarily make humans ill. Eat your own kind and you risk unleashing all kinds of hell. That was what the BSE crisis was all about. Ingestion of ground-up cattle brains in cheap cattle feed led to an epidemic of the bovine disease. A similar phenomenon was discovered in human beings in the 1950s. The Fore people of Papua New Guinea were eating their deceased relatives in order to absorb their strength and other qualities. Enormous numbers of them contracted kuru, a disease related to BSE, which killed hundreds of them.
Yet many more Fore women and children died of kuru than men (to the point where the women accused the men of using witchcraft to destroy them). Usually, in the traditional funeral rites, the men were given the prime cuts to eat muscle tissue while the women and children got the brains and organs, which harboured disease in far more virulent measure. The Fore men were largely fine, so you could argue that cannibalism is not necessarily a health hazard: its eating the wrong bits that kills you.
The real show-stopper for the human stem-cell burger is the bit that most of the media coverage glossed over. Growing those stem cells is not a matter of scattering them in a bed of organic grass. The cells are grown in a cocktail of antibiotics and fetal bovine serum. This is blood drawn from foetuses that have been removed from slaughtered pregnant cows.
At about 160 (or three cow foetuses, depending on how you want to look at it) a litre, this is the most expensive part of the whole process. It is also the most distasteful. Experiencing poor mouthfeel from a burger is one thing. Knowing a cow foetus has had its heart punctured and sucked dry in order to grow the meat is quite another.
Medical researchers get through roughly half a million litres of fetal bovine serum a year because its hormones and growth factors are so essential to stem-cell growth. There are problems with it, though. The chemicals it contains can skew the outcome of experiments. In addition, the serum is extracted in a slaughterhouse, with no anaesthetic, and research shows that the foetus probably feels pain or discomfort.
View post:
Yes, you can make a burger out of human stem cells - but you probably wouldn't want to
Posted in Stem Cells
Comments Off on Yes, you can make a burger out of human stem cells – but you probably wouldn’t want to
Yes, you can make a burger out of human stem cells – but you probably wouldn't want to
Posted: August 22, 2013 at 4:44 pm
After the success of the test-tube burger, Michael Brooks answers the question on everyone in the NS offices lips: "Why not make burgers from human stem cells?"
You are what you eat - or at least you might be. Photograph: Getty Images.
Sometimes the NSs offices resound with provocative questions. Last week, it was: Why not make burgers from human stem cells?
This is not as ridiculous as it might first seem. It would be the pinnacle of ethical carnivorous living, the only way you could eat prime meat with the full, informed consent of the donor.
It wouldnt be cheap. The price of a burger cultured from human cells would make the 250,000 feed, created by the Maastricht University researcher Mark Post and formally presented on 5 August, look like a bargain. Human stem-cell culture for medical research is done under the most onerous safety restrictions and following strict protocols. Culturing human cells for human consumption would be just as onerous (and thus expensive) as it is for medical research because we would have to make sure there was no chance the cells could become infected by viruses or bacteria.
Eating other animals is safer simply because the pathogens that make them ill do not necessarily make humans ill. Eat your own kind and you risk unleashing all kinds of hell. That was what the BSE crisis was all about. Ingestion of ground-up cattle brains in cheap cattle feed led to an epidemic of the bovine disease. A similar phenomenon was discovered in human beings in the 1950s. The Fore people of Papua New Guinea were eating their deceased relatives in order to absorb their strength and other qualities. Enormous numbers of them contracted kuru, a disease related to BSE, which killed hundreds of them.
Yet many more Fore women and children died of kuru than men (to the point where the women accused the men of using witchcraft to destroy them). Usually, in the traditional funeral rites, the men were given the prime cuts to eat muscle tissue while the women and children got the brains and organs, which harboured disease in far more virulent measure. The Fore men were largely fine, so you could argue that cannibalism is not necessarily a health hazard: its eating the wrong bits that kills you.
The real show-stopper for the human stem-cell burger is the bit that most of the media coverage glossed over. Growing those stem cells is not a matter of scattering them in a bed of organic grass. The cells are grown in a cocktail of antibiotics and fetal bovine serum. This is blood drawn from foetuses that have been removed from slaughtered pregnant cows.
At about 160 (or three cow foetuses, depending on how you want to look at it) a litre, this is the most expensive part of the whole process. It is also the most distasteful. Experiencing poor mouthfeel from a burger is one thing. Knowing a cow foetus has had its heart punctured and sucked dry in order to grow the meat is quite another.
Medical researchers get through roughly half a million litres of fetal bovine serum a year because its hormones and growth factors are so essential to stem-cell growth. There are problems with it, though. The chemicals it contains can skew the outcome of experiments. In addition, the serum is extracted in a slaughterhouse, with no anaesthetic, and research shows that the foetus probably feels pain or discomfort.
View post:
Yes, you can make a burger out of human stem cells - but you probably wouldn't want to
Posted in Stem Cells
Comments Off on Yes, you can make a burger out of human stem cells – but you probably wouldn't want to